Vanda Pharmaceuticals, Inc. (VNDA) Announces The Appointment Of Chief Commercial Officer

WASHINGTON, April 20, 2015 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (Vanda) (NASDAQ: VNDA) today announced that it has named Tom Gibbs as Senior Vice President, Chief Commercial Officer of the company.  Mr. Gibbs has 20 years of experience in the pharmaceutical industry, including several senior-level leadership roles in global sales and marketing.

"We are very pleased to welcome Tom to the Vanda team," said Mihael H. Polymeropoulos, M.D., President and CEO of Vanda.  "His depth of industry experience and proven track record across a wide spectrum of therapeutic areas are expected to be pivotal to the commercial success of Vanda's global product portfolio."

Prior to joining Vanda, Mr. Gibbs served as Vice President of Worldwide Commercial Operations at Bristol Myers Squibb.  Prior to this position, Mr. Gibbs held other senior roles at Bristol Myers Squibb including Vice President of US HIV Franchise and Vice President Global Commercialization and FDT Leader HCV Portfolio and HCV Small Molecules.

Before joining Bristol Myers Squibb, Mr. Gibbs held the position of Vice President of US Sales for Novartis Vaccines and Diagnostics.  Earlier in his career, Mr. Gibbs held positions at Endo Pharmaceuticals, Johnson & Johnson Corporation, George Weiss Associates and SmithKline Beecham PLC.  Mr. Gibbs received his Bachelors of Science in Economics and a Masters of Business Administration from The Wharton School of the University of Pennsylvania.

ABOUT VANDA PHARMACEUTICALS INC.:
Vanda Pharmaceuticals Inc. is a biopharmaceutical company focused on the development and commercialization of products for the treatment of central nervous system disorders.  For more on Vanda Pharmaceuticals Inc., please visit www.vandapharma.com.

CAUTIONARY NOTE REGARDING FORWARD LOOKING STATEMENTS
Various statements in this release are "forward-looking statements" under the securities laws. Forward-looking statements are based upon current expectations that involve risks, changes in circumstances, assumptions and uncertainties. Important factors that could cause actual results to differ materially from those reflected in Vanda's forward-looking statements include, among others, Vanda's assumptions regarding the commercial success of its global product portfolio and other factors that are described in the "Risk Factors" and "Management's Discussion and Analysis of Financial Condition and Results of Operations" sections of Vanda's annual report on Form 10-K for the fiscal year ended December 31, 2014, which is on file with the SEC and available on the SEC's website at www.sec.gov. In addition to the risks described above and in Vanda's annual report on Form 10-K and quarterly reports on Form 10-Q, other unknown or unpredictable factors also could affect Vanda's results. There can be no assurance that the actual results or developments anticipated by Vanda will be realized or, even if substantially realized, that they will have the expected consequences to, or effects on, Vanda. Therefore, no assurance can be given that the outcomes stated in such forward-looking statements and estimates will be achieved.

Corporate Contact:
Jim Kelly
Senior Vice President and Chief Financial Officer
Vanda Pharmaceuticals Inc. 
(202) 734-3428
[email protected]

Media Contact:
Laney Landsman
Vice President
Makovsky
(212) 508-9643
[email protected]

To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/vanda-pharmaceuticals-announces-the-appointment-of-chief-commercial-officer-300068287.html

SOURCE Vanda Pharmaceuticals Inc.

Suggested Articles

The biotech behind AstraZeneca and the University of Oxford’s late-stage pandemic vaccine has hired Margaret (Meg) Marshall, M.D., as its new CMO.

On the heels of a merger and $60 million private offering, Compass is looking to go public. It filed to raise up to $50 million in its Nasdaq IPO.

he results suggest V114 provides broader protection from pneumococcal bacteria than Prevnar 13 does, positioning Merck to muscle in on Pfizer’s turf.